Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 63 publications
Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.
Journal: The New England journal of medicine
Published: January 28, 2026
Rb-driven transcription limits its tumour-suppressive effects in breast cancer.
Journal: Nature
Published: August 26, 2025
CDK4/6 inhibition enhances CAR-T cell therapy in solid tumors.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: July 19, 2025
Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor-Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 14, 2025
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer.
Journal: Journal for immunotherapy of cancer
Published: February 05, 2025
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion.
Journal: Cancer cell
Published: November 12, 2024
A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 15, 2024
The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer.
Journal: Future oncology (London, England)
Published: July 29, 2024
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion.
Journal: Cancer cell
Published: November 09, 2023
Last Updated: 09/26/2026